Pharmaceutical giant AstraZeneca is teaming up with tech powerhouse Oracle to use artificial intelligence to identify patients for clinical trials and monitor potential safety risks, aiming to speed up drug development and improve medical research.
The partnership will combine AstraZeneca’s drug development expertise with Oracle’s AI technology and health data capabilities to help researchers match patients to clinical trials and identify potential safety issues.
The collaboration will initially focus on cancer, cardiovascular and respiratory diseases, immunology and rare diseases, with the technology potentially helping doctors diagnose serious illnesses earlier.
Pascal Soriot, CEO of AstraZeneca, said the partnership could help researchers and healthcare providers improve patient care with AI-based technology.
“We can help clinicians identify patients earlier, optimize clinical trials, and continuously generate evidence throughout the lifecycle of a drug,” Soriot said in a statement.
The first project will focus on hypertension research in Abu Dhabi, in partnership with UAE-based healthcare company M42.
Patient recruitment remains a major hurdle in clinical research, with recruitment delays often extending trial timelines and increasing development costs.
AstraZeneca has also faced setbacks in its clinical trials, including delays related to a breast cancer treatment and the failure of a drug for nerve disorders, raising concerns about its drug development efforts, according to Reuters.
The companies signed a non-binding agreement and did not disclose financial terms.
The partnership comes as AstraZeneca seeks to expand its drug portfolio and reach more than $80 billion in annual revenue by 2030.
Reuters contributed to this report.
Gn bussni
